Metropolis Healthcare Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Investment phase pivots to harvest: Management declared the period of heavy investment "now done" after adding 90 labs and completing three acquisitions, shifting focus to margin expansion and integration-led returns.
• FY26 guided for ~26% headline growth: Organic revenue growth of ~12% (7% volume, 5% realization) plus acquired entities growing 13–14% combine for a guided 25–26% total revenue growth.
• Margin expansion of ~100 bps promised: Organic adjusted EBITDA margin expected to rise from 24.4% to ~25.4%, though reported margin will be 50–100 bps lower due to dilution from newly acquired, lower-margin Core Diagnostics.
• Core Diagnostics is the swing asset: Acquired for its 1,700-strong oncologist network, Core was breakeven in Q4; management targets high single-digit EBITDA by FY26 end and Metropolis-like profitability in 3 years, but integration dis-synergies and sub-scale margins create execution risk.
• What to watch next quarter: Whether Core Diagnostics and the two pending acquisitions consolidate on schedule in Q1, the pace of B2C volume recovery toward the 7% target, and any sign that the lab expansion margin drag is easing as guided.

The Pivot: From Investment to Harvest

• Four-year transformation completed: Management framed the last four years as a deliberate, bold investment cycle triggered by COVID, choosing to reshape the business for a changing industry rather than defend steady-state profits.
• Lab build-out now done: The planned addition of 90 labs is complete; FY26 will see only selective, single-digit lab additions to fill market gaps, substantially easing the margin pressure from rapid expansion.
• Collection center acceleration begins: With lab infrastructure in place, focus shifts to significantly scaling the collection center network and driving utilization across both new and existing assets through a focused productivity initiative.
• One-off cost burden clears: INR 21 crores of one-off costs in Q4 (mostly M&A-linked diligence and transaction fees for six evaluated deals, plus tax case legal costs and a small inventory provision) are not expected to recur in Q1 FY26.

Ameera Shah: "Our period of heavy investment is now done, and we can move to a phase of reaping the benefits of these investments via accelerated organic and inorganic growth and better margins."

Inorganic Strategy: Three Acquisitions, One Platform

• Core Diagnostics closed, two pending: Core Diagnostics (pan-India oncology testing leader) consolidated for 11 days in March; Scientific Pathology (Agra) and Dr. Ahujas' Pathology and Imaging Center (Dehradun) expected to consolidate by end of May, in Q1 FY26.
• North India revenue to nearly double: Contribution from North India expected to grow from 8% to approximately 14–15% in FY26, driven by these acquisitions and a "string of pearls" approach to entering underserved markets.
• Core Diagnostics acquisition rationale: The primary asset is Core's front-end connect with 1,700 oncologists across India, not its back-end machines or testing infrastructure; management plans to use Core as the platform to expand from oncogenomics into all other genomics categories.
• Core margin profile and synergy path: Core operates at lower gross margins (~60%) due to higher cost of goods as a specialty-driven business; Metropolis expects to lift this through procurement synergies, overlapping lab consolidation, and cross-selling Core's test menu through its own distribution network.
• Integration timeline and lab rationalization: Overlapping labs between Metropolis and Core are being consolidated; a clear combined lab count is expected by end of Q1 FY26. Combined, all three acquisitions add fewer than 10 labs.
• M&A pause signaled: Management is not actively looking to close any deals in the next 3–6 months, though open to opportunities if ongoing discussions conclude.

Ameera Shah: "The main reason we acquired Core was because of the doctor connect that Core has with the 1,700 oncologists across the country, not so much for the machines or the back-end testing, but really for the front-end connect."

Revenue Growth: Organic Engine and Mix Shift

• FY25 growth split evenly: 12% YoY revenue growth came 6% from patient volume increase and 6% from micro market-enabled pricing and test mix improvements.
• B2C is the primary growth driver: B2C revenues grew 17% in FY25, driven by granular micro-marketing, deeper penetration into smaller towns, and product mix shift toward larger packages; Maharashtra B2C grew 19% YoY.
• TruHealth wellness segment scaling: Grew 24% YoY, now contributing 19% of total revenues at Q4 exit run rate, driven by portfolio enhancements including Vital checkups, doctor consultations, and ECG services.
• Tier 3 towns gaining share: 18% YoY revenue growth, now 26% of domestic revenues, supported by clinician outreach programs; presence expanded to 750 towns from 350 a couple of years ago.
• Specialty segment building depth: Grew 13% YoY in FY25 with 60 new tests added across oncology, women and child health, chronic diseases, nephrology, and molecular genomics; expected to contribute more meaningfully with Core's capabilities.
• B2B rationalization complete: The deliberate exit from low-margin institutional and government contracts ran for one full year and is now over; from Q1 onwards, the company will start rebuilding a good-quality institutional business targeting 10–12% growth.
• Q4 softness was transient: Lower-than-usual February revenue from reduced acute testing volumes due to seasonal weather changes; March saw healthy recovery and April followed normal trends.
• FY26 organic growth guided at ~12%: 7% patient volume growth plus 5% realization improvement; B2C targeted at 14–15% growth, B2B at 10–12%. Acquired entities expected to grow 13–14%, taking combined growth to 25–26%.

Margin Trajectory: Expansion with a Dilution Overhang

• Organic margin expansion of ~100 bps targeted: Adjusted EBITDA margin on the organic business expected to move from 24.4% to ~25.4% in FY26, driven by productivity initiatives, operational efficiencies, and lower incremental costs from infrastructure upgrades.
• Core Diagnostics creates a reported margin drag: Because Core is currently at breakeven with lower gross margins, consolidated reported margin may be 50–100 bps below the organic number.
• Core margin ramp planned in steps: From breakeven in Q4 FY25 to high single-digit EBITDA (8–9%) by end of FY26, and toward Metropolis-like profitability in 3 years; management notes that even at its current ~INR 110 crore revenue scale, Core will start making profit within the Metropolis group due to cost synergies.
• Lab expansion drag persists but fades: The margin pressure from the rapid lab build-out over the last two years will partially impact FY26 and some part of FY27; it will take two more financial years to completely vanish.
• Gross margin stability expected: Gross margin has held around 80% for approximately eight quarters; no further pressure anticipated on organic gross margins.
• Capex declining: Organic capex for FY26 guided at INR 50–55 crores, down from INR 60–70 crores in prior years, reflecting the end of the heavy lab investment cycle.

Competitive Position and Operating Model

• Scientific expertise remains the moat: Management emphasized that while technology, distribution, and commercials matter, the core of the business remains the scientific expertise the company brings, particularly as it expands specialty and genomics testing.
• Health-tech competitive pressure fading: Management noted that health-tech players are no longer visible or aggressive, either on the ground or from a funding perspective, reducing a source of competitive intensity.
• Micro-market pricing strategy in play: Q4 FY25 saw price increases in 4–5 select markets alongside price rationalization in others, with a net impact of approximately 2 percentage points; no further price changes planned for the next 2–3 quarters.
• B2C growth structurally sustainable: Growth comes from three recurring sources: collection center network expansion in core markets, product mix shift toward larger packages, and additional services (basic radiology, vital checks) at centers; no non-recurring element.
• New B2C markets identified: Management has picked about four new markets beyond West and South (including one in North) to deepen B2C penetration, though not naming them for competitive reasons.

Ameera Shah: "While technology, while distribution, while commercials, all of them are important, the core of the business still remains the scientific expertise that we bring to the table."

Guidance & Commitments

Key Metrics